Legal & General Group Plc increased its position in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 1.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 61,371 shares of the specialty pharmaceutical company’s stock after buying an additional 770 shares during the period. Legal & General Group Plc’s holdings in AMAG Pharmaceuticals were worth $1,384,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Advisors Asset Management Inc. increased its position in AMAG Pharmaceuticals by 259.9% in the first quarter. Advisors Asset Management Inc. now owns 6,931 shares of the specialty pharmaceutical company’s stock worth $156,000 after buying an additional 5,005 shares during the last quarter. Mason Street Advisors LLC increased its position in AMAG Pharmaceuticals by 7.4% in the first quarter. Mason Street Advisors LLC now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 554 shares during the last quarter. Sei Investments Co. increased its position in AMAG Pharmaceuticals by 0.7% in the first quarter. Sei Investments Co. now owns 8,342 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 54 shares during the last quarter. Affinity Investment Advisors LLC increased its position in AMAG Pharmaceuticals by 51.4% in the first quarter. Affinity Investment Advisors LLC now owns 9,747 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 3,310 shares during the last quarter. Finally, Baird Financial Group Inc. bought a new position in AMAG Pharmaceuticals during the first quarter worth about $220,000.
Shares of AMAG Pharmaceuticals, Inc. (AMAG) opened at 18.85 on Friday. The firm’s 50-day moving average is $18.77 and its 200 day moving average is $21.08. The stock’s market capitalization is $660.60 million. AMAG Pharmaceuticals, Inc. has a 12-month low of $16.00 and a 12-month high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.34 by $1.74. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.45 earnings per share. On average, equities research analysts forecast that AMAG Pharmaceuticals, Inc. will post $5.40 EPS for the current fiscal year.
AMAG has been the topic of a number of research reports. Jefferies Group LLC set a $40.00 target price on shares of AMAG Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, April 20th. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price objective on the stock in a report on Tuesday, July 11th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. TheStreet downgraded shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Finally, Barclays PLC restated an “equal weight” rating and set a $20.00 price objective (down previously from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $28.09.
In other news, SVP Julie Krop sold 4,938 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the sale, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by insiders.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
